Leukapheresis Market Summary

• The global leukapheresis market was valued at USD 1.15 billion in 2025 and is projected to reach USD 2.45 billion by 2034.

• The market is expected to expand at a CAGR of 8.8% during the forecast period 2026-2034, propelled by the surge in CAR-T cell therapy clinical trials and approvals, rising prevalence of leukemia and autoimmune disorders, and technological advancements in automated apheresis systems.

• By product type, the leukapheresis devices (apheresis systems) segment dominated the market with a 48% share in 2025.

• By type, the therapeutic leukapheresis segment dominated the market with a 58% share in 2025.

• By application, the cell therapy and research segment dominated the market with a 42% share in 2025.

• By end-user, the blood component providers and blood centers segment dominated the market with a 45% share in 2025.

• North America accounted for the largest share of the leukapheresis market at 48% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Leukapheresis is a specialized medical procedure in which white blood cells (leukocytes) are selectively separated and extracted from a patient's or donor's blood, while the remaining blood components (red blood cells, platelets, and plasma) are returned to circulation. The leukapheresis market comprises apheresis devices, specialized disposable leukapheresis sets, columns, and cell separation reagents used for both therapeutic depletion and donor collection. The scope of this report encompasses leukapheresis systems and consumables utilized in clinical treatment, cell therapy manufacturing (including CAR-T and TIL therapies), research applications, and blood banking. By product type, the market spans apheresis equipment, disposables & kits, and leukoreduction filters. By type, it is categorized into therapeutic leukapheresis and donor/preparative leukapheresis. By application, it divides into cell therapy & immunotherapy research, leukemia & lymphoma management, autoimmune diseases, and others. By end-user, it includes blood centers, hospitals & specialty clinics, and academic & research institutes. The market is propelled by the rapid expansion of adoptive cell transfer therapies, growing leukemia incidence, and automated apheresis innovations.

Leukapheresis Market Key Growth Drivers

• Exponential expansion of CAR-T cell therapies and adoptive cell immunotherapies, which require high-purity leukapheresis starting material (leukopak harvest) for autologous and allogeneic cell manufacturing.

• Increasing global incidence of hematologic malignancies, such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), necessitating therapeutic leukapheresis for hyperleukocytosis management.

• Continuous technological innovations in continuous flow centrifugation, automated interface control, and closed-system single-use apheresis disposables that enhance cell yield and donor safety.

• Surge in clinical development pipelines for cell and gene therapies worldwide, driving substantial demand for human leukapheresis products among biopharmaceutical companies and CROs.

• Expanding clinical applications of leukapheresis in severe autoimmune conditions and immune modulation therapies.

• Rising healthcare infrastructure investments and growth of blood transfusion networks across emerging economies in Asia-Pacific and Latin America.

• Well-established regulatory pathways and favorable reimbursement coverage for therapeutic apheresis procedures across developed healthcare markets.

Key Companies in Leukapheresis Market

The competitive landscape is led by the following active manufacturers:

• Terumo BCT, Inc. (Terumo Corporation)

• Fresenius Kabi AG

• Haemonetics Corporation

• Asahi Kasei Medical Co., Ltd.

• Macopharma SA

• Miltenyi Biotec B.V. & Co. KG

• STEMCELL Technologies Inc.

• Baxter International Inc.

• B. Braun Melsungen AG

• Bio-Rad Laboratories, Inc.

Factors Contributing to the Growth of the Leukapheresis Market

Market Drivers

Surge in CAR-T Cell Therapy and Adoptive Immunotherapies

The primary catalyst driving the leukapheresis market is the rapid rise of CAR-T cell therapies and cellular immunotherapies. Leukapheresis serves as the foundational, non-negotiable step in the harvest of mononuclear cells (MNCs) required for gene-edited T-cell manufacturing. Commercial approvals for cell therapies targeting hematologic cancers, combined with hundreds of active clinical trials investigating autologous and allogeneic treatments, have dramatically expanded the demand for standardized, high-yield leukapheresis products and closed-system processing kits.

Rising Incidence of Leukemia and Hematologic Disorders

The increasing global burden of blood cancers, specifically acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic leukemias, is a direct clinical driver. In severe hyperleukocytosis cases, therapeutic leukapheresis is urgently required to physically clear excessive white blood cells and prevent life-threatening leukostasis complications. Growing leukemia prevalence, supported by enhanced diagnostic capabilities, ensures steady hospital utilization of apheresis devices and disposable tubing sets.

Market Restraints

Despite substantial growth momentum, the leukapheresis market faces several operational and clinical challenges. The high capital cost of advanced apheresis machines, combined with the recurring expense of specialized single-use disposable sets and apheresis kits, poses a financial strain on healthcare centers in low- and middle-income regions. Technical complexities and the requirement for highly trained apheresis nurses and cell-processing specialists present further operational bottlenecks. Furthermore, donor/patient safety concerns, such as citrate toxicity, transient hypocalcemia, hypotensive reactions, and vascular access complications, require rigorous clinical oversight. Supply chain vulnerabilities for sterile single-use tubing sets and regulatory hurdles surrounding cellular raw materials also impact market expansion.

Leukapheresis Market Segment Analysis

The leukapheresis market is segmented by product type (leukapheresis devices, disposables & kits, and leukoreduction filters), by type (therapeutic leukapheresis and donor/preparative leukapheresis), by application (cell therapy & research, leukemia & lymphoma management, autoimmune diseases, and others), by end-user (blood centers, hospitals & specialty clinics, and academic & research institutes), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Product Type

Dominant Subsegment: Leukapheresis Devices (Apheresis Systems).

The leukapheresis devices segment accounted for a 48% share of the leukapheresis market in 2025. Automated apheresis machines constitute the essential hardware foundation for clinical and donor cell separation. Premium multi-component collection systems equipped with continuous-flow technology command significant market value. Meanwhile, the disposables and kits segment is projected to register rapid recurring growth driven by procedural volume expansion.

By Type

Dominant Subsegment: Therapeutic Leukapheresis.

The therapeutic leukapheresis segment accounted for a 58% share of the market in 2025. Therapeutic applications dominate due to acute clinical demand in treating severe hyperleukocytosis in leukemia patients, as well as therapeutic depletion protocols for inflammatory and autoimmune conditions. Donor leukapheresis is expanding rapidly in parallel, fueled by the rising collection of leukopaks for cell therapy manufacturing.

By Application

Dominant Subsegment: Cell Therapy and Research.

The cell therapy and research segment accounted for a 42% share in 2025. The explosive commercial growth of CAR-T therapeutics, TCR therapies, and NK cell therapies has transformed leukapheresis into a pivotal biomanufacturing upstream process, establishing cell therapy as the largest and fastest-growing application category.

Leukapheresis Market Region Analysis

Dominant Region: North America

North America accounted for a 48% share of the global leukapheresis market in 2025. The region's dominant position is driven by a high concentration of commercial cell therapy developers, extensive clinical trial pipelines, well-established healthcare reimbursement systems (CPT coding for apheresis), and robust blood processing infrastructure. The United States represents the single largest country market globally, supported by major academic medical centers and active commercialization of CAR-T therapies.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. Growth is driven by expanding healthcare infrastructure, rising leukemia prevalence, rapidly growing clinical trial activity for CAR-T immunotherapies in China, and increasing investments by leading biopharmaceutical manufacturers across Japan, South Korea, and India.

Regional Commentary

North America

North America leads market value, holding a 48% share in 2025. High cell therapy research activity, commercial CAR-T manufacturing hubs, and sophisticated apheresis centers maintain its leading edge.

Europe

Europe represents a highly mature market anchored by strong healthcare systems, standardized apheresis protocols, and prominent academic cell therapy research institutes across Germany, France, the UK, and Italy.

Asia-Pacific

Asia-Pacific is the primary growth engine driven by rapid clinical trial growth in China, expanding blood center capacity, and rising healthcare expenditure across emerging economies.

Rest of World

Rest of World (Middle East, Africa, South America) displays steady expansion supported by healthcare infrastructure modernization and growing access to specialized blood component separation technologies.

Leukapheresis Market Competitive Landscape

The global leukapheresis market is classified as Consolidated. A select group of medical device and bioprocess technology leaders, including Terumo BCT, Fresenius Kabi, Haemonetics, Asahi Kasei Medical, Miltenyi Biotec, and Macopharma, command significant market share through established apheresis instrument installed bases, proprietary separation technologies, and global distribution networks.

• Market concentration: Consolidated, with leading multinational medical technology companies holding the majority of equipment installed bases and single-use tubing set supply agreements.

• Leading players: Terumo BCT (Spectra Optia system), Fresenius Kabi (Amicus, COM.TEC), Haemonetics, Miltenyi Biotec (CliniMACS Prodigy), Asahi Kasei Medical, Macopharma, STEMCELL Technologies, and B. Braun.

• Geographic reach: Major players operate extensive global commercial and technical service networks, providing ongoing maintenance, specialized staff training, and reliable disposable set distribution across hospitals and blood centers.

• Product portfolio strength: Competitive differentiation hinges on continuous-flow separation efficiency, automated interface controls, low extracorporeal blood volume requirements, and closed-system integration for cell therapy workflows.

• Pipeline strength: Development priorities emphasize automated cell selection, digital monitoring integration, closed-system GMP cell separation platforms, and high-yield leukopak harvesting systems.

• Strategic partnerships: Active collaborations between apheresis equipment manufacturers, contract development and manufacturing organizations (CDMOs), and cell therapy biopharmas to standardize apheresis collection protocols.

• M&A activity: Strategic acquisitions focused on acquiring specialized cell isolation reagents, microfluidic cell separation assets, and expanding blood center supply distribution capabilities.

• Innovation focus: Focus on reducing apheresis procedure times, maximizing targeted immune cell yields, minimizing donor fatigue, and automating cell separation for point-of-care manufacturing.

• Regulatory standing: FDA 510(k) clearances, CE mark certifications, and ISO compliance for blood processing devices and single-use sterile medical sets represent essential market entry credentials.

Leukapheresis Market Recent Developmental Activities

In 2024-2025, Terumo BCT advanced its Spectra Optia Apheresis System capabilities. Strategic significance: Expanded software and disposable set integrations specifically tailored for CAR-T cell starting material collection, ensuring high mononuclear cell purity and cell viability for cell therapy manufacturing.

In 2024, Fresenius Kabi enhanced its Amicus Separation System workflows. Strategic significance: Introduced updated clinical protocols and expanded disposable kit offerings to streamline therapeutic leukapheresis and donor mononuclear cell collection for biopharmaceutical developers.

Leukapheresis Market Segmentation

Leukapheresis Market Assessment by Product Type

• Leukapheresis Devices (Apheresis Systems)

• Disposables & Kits

• Leukoreduction Filters

Leukapheresis Market Assessment by Type

• Therapeutic Leukapheresis

• Donor / Preparative Leukapheresis

Leukapheresis Market Assessment by Application

• Cell Therapy & Research

• Leukemia & Lymphoma Management

• Autoimmune Diseases

• Others

Leukapheresis Market Assessment by End-User

• Blood Component Providers & Blood Centers

• Hospitals & Specialty Clinics

• Academic & Research Institutes

Leukapheresis Market Assessment by Geography

• North America

 United States Leukapheresis Market Size in USD million (2023-2034)

 Canada Leukapheresis Market Size in USD million (2023-2034)

 Mexico Leukapheresis Market Size in USD million (2023-2034)

• Europe

 France Leukapheresis Market Size in USD million (2023-2034)

 Germany Leukapheresis Market Size in USD million (2023-2034)

 United Kingdom Leukapheresis Market Size in USD million (2023-2034)

 Italy Leukapheresis Market Size in USD million (2023-2034)

 Spain Leukapheresis Market Size in USD million (2023-2034)

 Rest of Europe Leukapheresis Market Size in USD million (2023-2034)

• Asia-Pacific

 China Leukapheresis Market Size in USD million (2023-2034)

 Japan Leukapheresis Market Size in USD million (2023-2034)

 India Leukapheresis Market Size in USD million (2023-2034)

 Australia Leukapheresis Market Size in USD million (2023-2034)

 South Korea Leukapheresis Market Size in USD million (2023-2034)

 Rest of Asia-Pacific Leukapheresis Market Size in USD million (2023-2034)

• Rest of the World

 Middle East Leukapheresis Market Size in USD million (2023-2034)

 Africa Leukapheresis Market Size in USD million (2023-2034)

 South America Leukapheresis Market Size in USD million (2023-2034)

Key Takeaways from the Leukapheresis Market Report Study

• Market size analysis for the current Leukapheresis market size (2025), and market forecast for 9 years (2026 to 2034).

• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that have happened over the last 3 years.

• Key companies dominating the global Leukapheresis market.

• Various opportunities available for competitors in the Leukapheresis market space.

• What are the top-performing segments in 2025? How will these segments perform in 2034?

• Which are the top-performing regions and countries in the current Leukapheresis market scenario?

• Which are the regions and countries where companies should concentrate their opportunities for Leukapheresis market growth in the future?

Target audience who can benefit from this Leukapheresis market report study

• Leukapheresis product providers

• Research organizations and consulting companies

• Leukapheresis -related organizations, associations, forums, and other alliances

• Government and corporate offices

• Start-up companies, venture capitalists, and private equity firms

• Distributors and traders dealing in Leukapheresis 

• Various end-users who want to know more about the Leukapheresis market and the latest technological developments in the Leukapheresis market.